Strategic Patient Identification and Delivery of CAR-T Therapy in R/R DLBCL

Megan Melody, MD*, a malignant hematologist specializing in lymphoma and cellular therapy at Tampa General Hospital, shares practical considerations for strategically identifying and delivering Chimeric Antigen Receptor T-cell (CAR-T) therapy to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). She discusses her insights on common physician barriers and misperceptions, early patient identification and referral strategies, and practical approaches for reducing patient barriers. In this video, Dr Melody recommends CAR-T centers work closely with oncologists to ensure timely referral, equitable access, and seamless transitions of care for all patients eligible for CAR-T therapy.

*Paid consultant for Kite Pharma.